Local gyrification index, which measures cortical folding in the brain, could be a novel neuroimaging marker for major depressive disorder.
List view / Grid view
Major depressive disorder (MDD)
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
A new study has revealed how ketamine exerts its antidepressant effect, raising hopes of finding new treatment options for the disease.
Having resolved the structure of psychedelic drugs bound to the 5-HT2A serotonin receptor researchers are now developing new therapeutic drugs.
Detailed knowledge of the human genome can provide us with extensive information about the causes of disease and how patients will respond to treatments. In this article, Pushpanathan Muthuirulan explores the concept of genetic testing and the potential for pharmacogenomic testing to transform healthcare.
Drug Target Review explores research that suggests the microbiome could be a therapeutic target for major depressive disorder and what treatment options are now in the pipeline as a result of this association.